Jan 09, 2024 / 04:15PM GMT
Jess Fye JPMorgan-Analyst
Great. Good morning, everyone. Welcome. I'm Jess Fye, senior biotech analyst at JPMorgan. And we're continuing the conference this morning with Intra-Cellular. I'm joined by the company's CEO, Sharon Mates. She's going to give a presentation on the business, and then we're going to go into Q&A.
(Conference Instructions) So with that, let me pass it over to Sharon.
Sharon Mates Intra-Cellular Therapies - Inc. - Founder, Chairman & CEO
Thanks, Jessica. It's great to be here today. And I am joined by my colleagues, Mark Neumann, our Chief Commercial Officer; and Suresh Durgam, our Chief Medical Officer.
So before I begin, I should tell you that our presentation today does contain forward-looking statements and actual results may differ. And I refer you to our website and to our SEC filings for continuous updates on the company.
So today, I'm going to tell you about Intra-Cellular Therapies and about the great progress we've made and what we think is a great year that we've had
Intra-Cellular Therapies Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers